Group items tagged

With conventional corticosteroid treatment being effective in only 50-60% of patients, development of new treatment options is necessary to cover the unmet needs of the uveitis market. The market is currently dominated by corticosteroid treatment options and off-label immunosuppressive and biologic drugs. Although anterior uveitis patients constitute the major share of patients, except one, all the new treatments in late stage clinical development target the intermediate, posterior and pan uveitis patient segment. Drugs capable of permanently inhibiting ocular inflammation as well as offering an improved safety profile will have a significant impact on the uveitis market.

Unmet needs in hematologic malignancies calls for companies focusing on PI3Ks and BTK inhibitors to offer better treatment options. Around USD 10 bn has already been invested in licensing and acquisition of PI3K and other kinase inhibitors since the last five years. Targeting kinases have been on the agenda of most drug developers as they hold the key path to signaling, development and growth of the cell. Large global pharma are constantly on the hunt for drugs with label expansion potential, longevity and blockbuster potential.

Treating refractory hematological malignancies unfold a host of competition and commercial opportunities. Approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts attract swarming competition. There is severe competition amongst the companies to launch new therapies for this indication. Companies leading in the race to launch such therapies include Ambit Biosciences, Onconova Therapeutics, SymBio Pharma, and Celgene.

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications.